AIM
VRTX icon

Alambic Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Alambic Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-9,820
Closed -$1.6M – 459
2018
Q1 		$1.6M Sell
9,820
-14,100
-59% -$2.3M 0.22% 164
2017
Q4 		$3.58M Sell
23,920
-300
-1% -$44.4K 0.43% 78
2017
Q3 		$3.68M Sell
24,220
-50
-0.2% -$7.53K 0.4% 84
2017
Q2 		$3.13M Buy
24,270
+4,310
+22% +$519K 0.38% 73
2017
Q1 		$2.18M Buy
19,960
+2,270
+13% +$200K 0.27% 120
2016
Q4 		$1.3M Buy
17,690
+1,480
+9% +$120K 0.23% 157
2016
Q3 		$1.41M Buy
16,210
+4,175
+35% +$395K 0.33% 96
2016
Q2 		$1.03M Buy
12,035
+2,050
+21% +$177K 0.26% 134
2016
Q1 		$794K Buy
+9,985
New +$903K 0.26% 141

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Alambic Investment Management's VRTX Position: Q2 2018 in Review

Alambic Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2018, closing a stake of 9,820 shares — an estimated $1.6M sold.

Alambic Investment Management first reported a position in VRTX in Q1 2016 and held it in 9 quarters. The position peaked at $3.68M in Q3 2017. 690 funds tracked by Wall St. Rank hold VRTX as of Q2 2018.

  • Alambic Investment Management reported no remaining Vertex Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Alambic Investment Management sold 9,820 Vertex Pharmaceuticals shares in Q2 2018, an estimated $1.6M.
  • Alambic Investment Management first reported a position in Vertex Pharmaceuticals in Q1 2016 and held it in 9 quarters.
  • Alambic Investment Management's Vertex Pharmaceuticals position peaked at $3.68M in Q3 2017.
  • 690 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2018.

Based on Alambic Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.